(Q24628743)

PubMed

1 July 2020

viral drug resistance

1 reference

20 August 2019

1 reference

17 September 2019

1 reference

28 September 2019

1 reference

3 November 2019

1 reference

18 December 2020

3

Soo-Yon Rhee

0 references

Robert W Shafer

5

object named as

Robert W Shafer

0 references

Vici Varghese

2

object named as

Vici Varghese

0 references

José María Gatell

4

object named as

Jose M Gatell

0 references

author name string

Jose-Luis Blanco

Journal of Infectious Diseases

1

0 references

1 reference

language of work or name

English

0 references

publication date

1 May 2011

14 references

23 March 2019

22 June 2019

20 August 2019

17 September 2019

28 September 2019

19 October 2019

3 November 2019

23 December 2019

26 April 2020

1 July 2020

18 December 2020

24 October 2022

25 October 2022

10 January 2024

14 references

23 March 2019

22 June 2019

20 August 2019

17 September 2019

28 September 2019

19 October 2019

3 November 2019

23 December 2019

26 April 2020

1 July 2020

18 December 2020

24 October 2022

25 October 2022

10 January 2024

203

0 references

issue

9

0 references

page(s)

1204-14

0 references

copyright license

Creative Commons Attribution-NonCommercial

2 references

25 October 2022

10 January 2024

1 reference

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Retroviral intasome assembly and inhibition of DNA strand transfer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Human immunodeficiency virus reverse transcriptase and protease sequence database

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Resistance to integrase inhibitors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Resistance to HIV-1 integrase inhibitors: A structural perspective

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Characterization and structural analysis of HIV-1 integrase conservation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3069732

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

30 May 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Evolution of raltegravir resistance during therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21459813

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIR025